INN Semaglutide
Dosage form: subcutaneous solution
Pharmacotherapeutic group: hypoglycemic medicine - glucagon-like peptide-1 analogue
Release form: prefilled disposable injection pen 1.34 mg/ml (1 pc).
Instructions
Quincenta® is the first domestic semaglutide with a full production cycle in the Russian Federation, used in the treatment of type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular diseases.
